HLB Panagene Turns to PNA-AOC as a New Approach for Duchenne Muscular Dystrophy
Duchenne muscular dystrophy (DMD) remains a major challenge for drug developers because many therapeutic approaches have struggled to deliver sufficient amounts of a treatment...
Sarcomatrix Plans First Human Trial of S-969 for Duchenne Muscular Dystrophy in 2027
For families affected by Duchenne muscular dystrophy (DMD), every new clinical development offers hope. While many promising therapies begin in the laboratory, the true...
DYNE-251 Phase 3 FORZETTO Clinical Trial of Z-Rostudirsen Officially Begins for DMD
Dyne Therapeutics has announced the start of the Dyne Therapeutics Phase 3 FORZETTO Trial (NCT07608432) of Z-Rostudirsen for DMD, marking another major step forward...
Del-Zota SAFARI44 Phase 3 Trial: A New Exon 44 Skipping Study for Duchenne Muscular Dystrophy
Duchenne muscular dystrophy (DMD) research continues to move forward with the launch of the Del-Zota SAFARI44 Phase 3 clinical trial evaluating AOC 1044, also...
BioMarin Launches BMN 351 Exon 51 Skipping Therapy Phase 2 Clinical Trial for Duchenne Muscular Dystrophy
BioMarin Pharmaceutical has officially launched a new Phase 2 extension study (NCT07573631) evaluating BMN 351, an investigational exon 51 skipping therapy designed for people...